Trevena, Inc. (NASDAQ:TRVN – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.24 and traded as low as $1.30. Trevena ...

为探究 CXCR4 和 S1P?相互作用机制，首尔国立大学研究人员发现二者可形成异源二聚体，S1P/S1P?轴单向调节 CXCR4，为免疫细胞 ...

3月19日，港股 创新药 企业云顶新耀（1952.HK）宣布，正式启动位于浙江嘉善工厂的伊曲莫德（VELSIPITY®）生产建设项目。这一举措将有力推动伊曲莫德的本地化生产进程，同时为公司的mRNA技术产业化战略奠定坚实基础。

为探究三阴性乳腺癌（TNBC）淋巴结转移机制，研究人员研究 MLPH 作用，发现其经特定轴抑制肿瘤进展，或为 TNBC 治疗提供新策略。 为了揭开 TNBC 淋巴结转移的神秘面纱，大连理工大学附属肿瘤医院（中国医科大学附属肿瘤医院、辽宁省肿瘤医院 & 研究所）等机构的研究人员踏上了探索之旅。他们的研究成果发表在《Journal of Translational Medicine》上，为 TNBC ...

Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

点击蓝字关注我们【导读】脑转移是表皮生长因子受体（epidermal growth factor receptor， ...

S.D. Standard Drilling PLC ( (DE:S1P)) just unveiled an update. S.D. Standard ETC Plc and Strategic Value Partners are exploring the sale of existing shares in Dolphin Drilling AS through an ...

Also emerging are oral therapies including Bristol-Myers Squibb's S1P therapy Zeposia (ozanimod) – with Arena Pharma's etrasimod following closely after in phase 3 – as well as newer JAK ...

Orally-active S1P agonist Zeposia (ozanimod) has been submitted to the FDA as a treatment for adults with moderately to severely active ulcerative colitis (UC), with a decision from the US ...

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

脑转移现象在肺腺癌患者中并不罕见，尤其是在66.3%带有表皮生长因子受体（EGFR）突变的非吸烟患者中更是高达29%在初诊时已被检测到脑转移。这一数据让人不禁担忧，越来越多的患者在接受靶向治疗后，脑转移的发生率从初诊时的25%上升至45%。如何应对这一挑战，成为了医学界亟待研究的问题。